How do I set a price alert for 2595.HK?

To set a 2595.HK price alert on Stock Alarm Pro, navigate to the 2595.HK quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for 2595.HK?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for 2595.HK. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for 2595.HK?

Stock Alarm Pro supports over 125 trigger types for 2595.HK: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about 2595.HK price changes?

2595.HK alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for 2595.HK alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for 2595.HK and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

2595.HK Company Intelligence - Business Model, Drivers & Risks

2595.HK(2595.HK)

$27.40—Stale · unknown old

WatchlistAsk SA Chart

2595.HK(2595.HK)

HKSE • Last print unknown ago

$27.40—Stale · unknown old

WatchlistAsk SA Chart Studio

2595.HK(2595.HK)

2595.HK

GenFleet Therapeutics (Shanghai) Inc. specializes in the development of innovative therapies for cancer, focusing on precision medicine and targeted therapies. The company leverages its proprietary technology platform to identify and develop novel drug candidates, primarily targeting the Chinese and broader Asian markets, which are experiencing rapid growth in oncology treatment demand.

HealthcareBiotechnologylow - The company has high fixed costs associated with R&D and regulatory compliance, with variable costs primarily linked to clinical trial expenses.

Business Overview

01Partnerships with pharmaceutical companies for drug development - % of total unknown

02Grants and funding for research initiatives - % of total unknown

03Potential future revenue from drug sales upon commercialization - % of total unknown

GenFleet primarily generates revenue through strategic partnerships with larger pharmaceutical companies, leveraging its proprietary drug discovery platform to develop targeted therapies. The company’s competitive advantage lies in its focus on precision medicine, which is increasingly relevant in oncology, and its ability to navigate the regulatory landscape in China effectively.

What Moves the Stock

Progress in clinical trials for lead drug candidates, particularly in oncology

Partnership announcements with major pharmaceutical companies

Regulatory approvals for new therapies in China

Market sentiment towards biotechnology stocks in Asia

Watch on Earnings

Clinical trial milestones achievedPartnership revenue generatedRegulatory approval timelines

Risk Factors

Regulatory changes in China affecting drug approval processes

Technological disruption in drug discovery methodologies

Intense competition from both domestic and international biotech firms

Potential for larger pharmaceutical companies to out-license similar technologies

Limited revenue streams leading to reliance on external funding

Potential liquidity issues if funding rounds do not materialize

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The biotechnology sector can be sensitive to economic cycles, particularly in terms of funding and investment, but demand for healthcare remains relatively stable even during downturns.

Interest Rates

High interest rates could increase the cost of capital for R&D funding, potentially delaying drug development timelines and impacting valuations.

Credit

minimal - The company does not heavily rely on credit markets for its operations.

Live Conditions

Russell 2000 FuturesS&P 500 FuturesDow Jones Futures